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Abstract von Willebrand factor (VWF) performs its he-
mostatic functions through binding to various proteins. The
A1 domain of VWF contains binding sites of not only
physiologically important ligands, but also exogenous
modulators that induce VWF-platelet aggregation. Sulfa-
tides, 3-sulfated galactosyl ceramides, that are expressed
on oligodendrocytes, renal tubular cells, certain tumor cells
and platelets, have been suggested to interact with VWF
under some pathological conditions. The binding of VWF
to sulfatide requires the A1 domain, but its binding sites
have not been precisely identiﬁed. Here, we report that
alanine mutations at Arg1392, Arg1395, Arg1399 and
Lys1423 led to decreased VWF–sulfatide binding. These
sites have been reported to be the binding sites for platelet
membrane glycoprotein (GP) Ib and/or snake venom
botrocetin, and, interestingly, are identical to the mono-
clonal antibody (mAb) NMC4 epitope previously reported
to inhibit the VWF-GPIb interaction. We observed that
NMC4 also inhibited VWF interaction with sulfatides in a
dose-dependent manner. Thus, we conclude that VWF
binding sites of sulfatide overlap those of platelet GPIb and
botrocetin.
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1 Introduction
von Willebrand factor (VWF) is a multimeric glycopro-
tein that plays a pivotal role in primary haemostasis.
VWF circulates in the blood as a multimer with heterol-
ogous molecular weights, assembled from subunits of
*250 kDa. The multimer sizes range from dimer of
*500 to [10,000 kDa. Mature VWF consists of 12
domains, which are arranged in the following sequence:
D0-D3-A1-A2-A3-D4-B1-B2-B3-C1-C2-CK. The D0 and
D3 domains adhere to and stabilize blood coagulation
factor VIII [1]. Activated platelet integrin aIIbb3 binds to
VWF through a segment that includes the tri-peptide
sequence Arg-Gly-Asp (RGD) in the VWF domain C1
[2]. Domain A3 has been shown to interact with collagen
in a variety of different experimental models [3–5]. Par-
ticular interest has been focused on the A1 domain, since
it contains binding sites for several molecules such as
platelet surface glycoprotein (GP) Iba [6, 7]. Exogenous
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bitiscetin [8] also bind to the VWF A1 domain. The A1
domain is the major VWF binding site for heparin [9, 10]
and unique sulfated glycolipid sulfatides [11–13].
Sulfatides are a group of cerebroside 3-sulfates, mainly
comprising 3-sulfate esters of galactosylcerebrosides
(galactosyl-3-sulfate esters) and found in mammalian tis-
sues as the corresponding cerebroside group. Sulfatide is a
major constituent of brain lipids and is found in trace
amounts in other tissues. It is an essential glycosphingolipid
in the peripheral as well as central nervous system, consti-
tuting 4–6 mole% of the total lipids in adult brain myelin. It
is expressed on the surface of several types of cells, such as
oligodendrocytes, renal tubular cells, certain tumor cell-
s,and platelets. Diverse biological processes are mediated
by sulfatide, including the regulation of cell growth protein
trafﬁcking, signal transduction, cell adhesion, neuronal
plasticity, morphogenesis and thrombogenesis [14–17].
Sulfated glycolipids are also constituents of normal eryth-
rocytes, but are not normally exposed; however, in sickle
cell anemia, reversible sickling and oxidant damage to the
membrane could modify and/or expose these molecules to
the surface [18, 19]. The interaction between VWF and
exposedsulfatide maycauseperiodicvaso-occlusion,which
is the severest manifestation of sickle cell anemia [20].
Based on the study on the binding of dispase-cleaved
VWF fragments, a sulfatide-binding site in the VWF A1
domain was localized between amino acids (AA) 1275 and
1436 [12]. Later, in 1995, it was reported that a synthetic
peptide spanning AA1391–1409 inhibited VWF binding to
bovine brain sulfatides [21]. To date, the precise binding
sites have not been determined and are controversial to
some measure. The aim of our study is to identify amino
acids responsible for binding to sulfatides, by the alanine-
scanning mutagenesis of VWF A1 domain, which has been
previously adopted to identify those of GPIb, botrocetin,
bitiscetin and heparin [7, 8, 10]. Here, we report that four
amino acids in the A1 domain are important for sulfatide
binding. Our ﬁndings are conﬁrmed by monoclonal anti-
body (mAb) inhibition study that blocks the VWF A1-
GPIb binding.
2 Methods
2.1 Materials
mAb NMC-4, which recognizes the A1 domain of
mature human VWF, was provided by Dr. Midori Shima
(Nara Medical University, Japan). Anti-human VWF
mAb B701, which has been reported to inhibit the
VWF–sulfatide interaction [12, 22], was a kind gift from
Dr. Dominique Meyer (INSERM University, France).
Anti-human VWF mAb 33E12 was generously provided
by Dr. Claudine Mazurier (CRTS, Lille, France). Anti-
human VWF polyclonal antibody (pAb) D082 and per-
oxidase-conjugated anti-human VWF antibody P0226
were purchased from Dako (Glostrup, Denmark). We
purchased sulfatide (cerebroside sulfate from the bovine
brain), O-phenylene diamine (OPD), bovine serum
albumin (BSA) and Tween-20 from Sigma (St Louis,
MO, USA). U-bottomed ELISA plates were obtained
from Nunc (Cambridge, MA, USA).
2.2 Plasmid constructs
The VWF segment targeted for mutagenesis consists of a
section of 254 amino acid residues between His1226 and
Gly1479 that contains the A1 domain and part of the D3
domain of mature human VWF. All 68 charged amino
acids including arginine, lysine, aspartate, glutamate and
histidine were changed singly or in small clusters to ala-
nine. They were covered in a total of 49 constructs (Fig. 1).
An expression plasmid, pSVvWF1.1, contains the full-
length coding sequence of human VWF. Numbering of
previously produced mutants started as +1 from the N-
terminal Ser of the mature, processed VWF subunit after
cleavage of the prepropeptide; thus, we renumbered all the
mutants, adding 763 to the old name [23] used in the
previous publications [7]. The names of clustered mutants
are abbreviated with the range of residue numbers and the
number of alanine substitutions [23].
Fig. 1 Amino acid residues of human VWF targeted for charged-to-
alanine mutagenesis. The amino acid sequence shown includes a part
of domain D3 (1226–1259) and the entire A1 domain (1260–1479).
The secondary structural elements of the A1 domain, as determined
by Celikel et al. [26], are indicated below the sequence (a, a-helix; b,
b-strand). Charged residues of His, Arg, Lys, Glu and Asp were
targeted for mutagenesis and are shown by characters in bold. A total
of 68 residues are covered by clustered or single mutants. A grey box
surrounds each construct. Every clustered mutant is underlined. For
example, construct 1226-HCD-1228 is named (1226–1228) 2A,
containing alanine substitutions at two charged residues, His1226
and Asp1228, while E1290A represents the mutant Glu1290 that was
changed to Ala
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1232.3 Expression of recombinant VWF
The preparation of recombinant VWF (rVWF) was
described previously [24]. Brieﬂy, human 293T cells,
growing in Dulbecco’s modiﬁed Eagle’s medium (Gibco-
BRL, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (Gibco-BRL), were transfected by the lipo-
fection method using TransFast transfection kit (Promega,
Madison, MI, USA) according to the manufacture’s
instructions. After 24 h, the cells were washed with phos-
phate-buffered saline (PBS, Gibco), and then incubated
with serum-free medium (Optimem-1, Gibco). After 48 h,
rVWF secreted in the medium was collected and concen-
trated using Centriprep-30 and Centricon-100 devices
(Millipore, Bedford, MA, USA). The amounts of rVWF
were measured by ELISA, as described elsewhere [24].
VWF multimer analysis of the mutants was previously
performed [7, 23]. Concentrated rVWF was diluted with
PBS containing 5% BSA (PBSA) and PBS, adjusted to
1 lg/ml (the ﬁnal BSA concentration was 1%). Diluted
rVWF was stored at -20C in aliquots until use.
2.4 Sulfatide-binding assay
We performed this assay according to the method of Fa-
valoro et al. [25] with some modiﬁcations. Brieﬂy, ELISA
plates were coated with 200 ll/well of sulfatide dissolved in
methanol at a ﬁnal concentration of 50 lg/ml and left
uncovered for 2 days at 4C to allow the methanol to
evaporate. After washing three times with washing buffer
(0.12 M NaCl, 0.02 M imidizole, 0.005 M citric acid, 0.1%
BSA), the plates were incubated for 1 h with 200 llo f5 %
PBSA to reduce non-speciﬁc background binding. The
plates were re-washed twice and incubated with 35 llo f
rVWF diluted with 3% PBSA (150 ng/ml, ﬁnal) for 2 h at
room temperature (RT). We used culture medium of 293T
cells withouttransfection asamockcontrol.Theplates were
re-washed four times and incubated with the secondary
antibody P0226 diluted in 3% PBSA (100 ll/well). After
washing ﬁve times, 100 ll of OPD solution (400 lg/ml)
was added followed by color development at 492 nm stop-
ped by adding 2 N H2SO4 (50 ll/well). Independent
duplicated experiments were performed three times. We
conﬁrmed thelinearrelationshipbetweentheopticaldensity
(OD) and concentration of added rVWF within the range of
0–200 ng/ml of rVWF (data not shown). We deﬁned the
relative percentage of sulfatide binding as follows:
OD value of mutant=OD value of WT ðÞ   100 % ½ 
2.5 Epitope mapping of mAb B701
The binding assay of mAb to rVWF by ELISA has been
described previously [23]. Brieﬂy, round-bottomed ELISA
plates were coated for 24 h at 4C with 25 ll of B701,
7.5 lg/ml, in 0.1 M sodium carbonate, pH 9.6. The wells
were washed with PBS containing 0.1% Tween 20 (PBS-
T) and then incubated for 2 h at room temperature (RT)
with 15 ll of various concentrations of wild-type or
mutant rVWF diluted in 3% PBSA. The wells were
washed three times in PBS-T and incubated for 1 h at RT
with 20 ll of P0226 1:2000 diluted in 3% PBSA. The
plates were washed three times, followed by color
development of OPD solution, as described earlier.
Binding of rVWF mutants was determined at a ﬁxed
concentration of rVWF (500 ng/ml) and normalized to the
value obtained for wild-type rVWF. Control assays were
performed with concentrated conditioned media from
mock-transfected 293T cells that gave absorbance values
of zero. We deﬁned the relative binding percentage as
follows.
ðOD value of mutant=OD value of WTÞ 100 ½% 
2.6 Effect of monoclonal antibodies on VWF binding
to sulfatide
A volume of 20 ll of each mAb (NMC4, B701 and
33E12) diluted in 3% PBSA was mixed with 100 llo f
rVWF (ﬁnal concentrations of antibody and wild-type
rVWF were 0.42–26.7 lg/ml and 182 ng/ml, respec-
tively). After 15 min incubation at RT, 50 ll of the
mixture was added to wells of sulfatide-coated ELISA
plate, as described above. The wells were washed four
times and incubated for 1 h at RT with P0226. The
amounts of VWF bound to the ELISA plate were eval-
uated by measuring the OD value after adding the OPD
buffer. This experiment was performed in triplicate and
repeated at least twice. We deﬁned the OD value without
antibody as 100%. The inhibitory effect of antibody was
expressed as bound VWF rate:
ðODvalueateachconcentration=ODvaluewithoutantibodyÞ
 100½% 
2.7 Statistical analysis
The signiﬁcance of differences was evaluated by the Stu-
dent’s t-test, and all statistical tests were two-sided.
2.8 Crystallographic structural representations
The PDB ﬁle of the VWF A1 domain [26] was downloaded
from the RCSB PDB web site (http://www.rcsb.org/pdb/
home/home.do), and its spherical surface plots were pre-
pared with the program Swiss Pdb Viewer (downloadable
at http://us.expasy.org/spdbv/).
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3.1 Sulfatide binding assay
At the start of the study of alanine scanning mutagenesis,
several clustered mutants were generated, including (1290–
1294)3A, (1332–1336)5A, (1359–1362)2A, 1376–1379)2A,
(1392–1395)2A, (1405–1408)4A, (1419–1423)2A and
(1426–1430)3A [23]; thereafter, these were replaced by the
corresponding single mutants. The resulting charged-to-ala-
nine rVWF mutant panel [7] was used for the study of VWF
sulfatide binding. Mutants were expressed and secreted efﬁ-
ciently and the multimer distribution of all recombinant
proteins was similar to that of wild-type rVWF or plasma
VWF[7].Thefoldingofeachmutanthasbeenevaluatedusing
a panel of conformation-dependent monoclonal antibodies
[7]. Recognition of the A1 domain by these antibodies is
impaired by reduction or denaturation, and mutants D1277A,
D1283A, (1277–1283)2A, K1297A, (1312–1315)2A,
R1315A, (1371–1374)3A and R1374A have reportedly
shown markedly decreased binding to all 6 conformation-
dependent mAbs, suggesting that these substitutions caused
signiﬁcant misfolding of the A1 domain [7]. These mutants
were therefore excluded from further analysis [10].
Figure 2 indicates that 10 mutants, E1290A, R1308A,
R1392A, R1395A, R1399A, Lys1405A, K1408A,
H1419A, K1423A and K1430A, inhibited binding to sul-
fatide by more than 40% compared to wild-type rVWF.
The four particular mutants, R1392A, R1395A, R1399A
and K1423A, markedly inhibited binding by 68.2, 80.4,
65.3 and 66.4%, respectively, suggesting the importance of
these four residues for binding to sulfatide.
3.2 Epitope mapping of mAb B701
mAb B701 did not bind to rVWF, lacking either the A1 or
A1 + A3 domain. However, B701 bound to rVWF lacking
onlytheA3domain(datanotshown).Therefore,B701binds
to the VWF-A1 domain, and Fig. 3 indicates that B701 lost
the ability to bind to two particular mutants, K1348A and
(1320–1326)4A.TheresultssuggestthatGlu1320,His1322,
Asp1323, His1326 and Lys1348 are candidates for the epi-
tope of B701. B701 has been reported to disturb the VWF–
sulfatide association [12, 22], but the epitope we identiﬁed
was distinct from the candidate sulfatide binding site,
Arg1392, Arg1395, Arg1399 and Lys1423, of which the
mutation inhibited the binding to sulfatide (Fig. 2).
3.3 Effect of mAbs for sulfatide binding
to VWF A1 domain
We studied the inhibitory effect of mAbs NMC4 and B701
that may interfere with VWF binding to GPIb or sulfatide.
Figure 4 indicates that NMC4 blocked sulfatide binding in
a dose-dependent manner, suggesting that NMC4 may
interact with the sulfatide binding sites on the A1 domain.
Fig. 2 Histogram of VWF binding to sulfatide. Wild- type or mutant
rVWF, in comparison with the mock control (indicated on the left),
was immobilized on ELISA plates coated with sulfatide. The relative
sulfatide binding of each alanine mutant is shown as: (OD value of
mutant/OD value of WT) 9 100 (%). The results represent the means
(±SD) of three independent experiments. The asterisk denotes a
statistically signiﬁcant difference compared to the control (P\0.05).
Relative binding of\60% is shown by the dashed line
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sulfatide binding. Control IgG 33E12, whose epitope is
located in the VWF C-terminal region and has no effect on
the interaction between the A1 domain and other proteins
[23, 27], showed no effect on sulfatide binding (Fig. 4).
Even higher concentrations of B701 (ﬁnal: 30–120 lg/mL)
did not inhibit sulfatide binding (data not shown). Taken
together with the sulfatide-binding assay results of our
mutants, the results of the epitope mapping experiment of
B701 (Fig. 3) suggests that B701 may not interact with the
VWF–sulfatide binding site. On the other hand, sulfatide-
binding sites may overlap with the platelet GPIb-binding
sites, and, thus, mAb NMC4 appears to interfere with not
only VWF binding to GPIb, but also to sulfatide.
3.4 Crystallographic structural representations
We addressed the locations of the putative binding sites of
sulfatide and B701 in the three-dimensional structure of the
VWF A1 domain as well as those of platelet GPIb and mAb
NMC4. Our study indicated that four mutations at Arg1392,
Arg1395, Arg1399 and Lys1423 markedly reduced the
binding to sulfatide (Fig. 2). The ﬁrst three are proposed
GPIb-binding sites [7] located on the a4 helix (Fig. 1) and
Fig. 5ashowsthattheseresidues(orange)arelocatedcloseto
each other on the surface of the molecule, although Lys1423
is located on the neighboring a5 helix. We then mapped
several amino acid residues whose alanine mutants showed
moderately decreased sulfatide binding (Fig. 2). Glu1290,
Arg1308, Lys1405, Lys1408, His1419 and Lys1430 are
distributedontheA1surface,butarelocatedinadistinctarea
from Arg1392, Arg1395 and Arg1399 (Fig. 5).
Fig. 3 Mapping of mAb B701 epitope. The epitopes of mAb B701
were analyzed by binding each rVWF to B701-coated ELISA plates.
Relative binding is shown as: (OD value of mutant/OD value of
WT) 9 100 [%]. The results represent the means (±SD) of three
independent experiments. The asterisk denotes a statistically signif-
icant difference compared to the control (P\0.05). Relative binding
of\60% is shown by the dashed line
Fig. 4 Inhibitory effects of mAb NMC4 and B701 on VWF–sulfatide
binding. mAb NMC4, B701 and the control antibody 33E12 were
tested for their inhibitiory effects on VWF–sulfatide binding. Serially
diluted mAbs were mixed with a ﬁxed concentration of WT rVWF
(182 lg/ml). After incubation for 30 min, the mixture was applied to
sulfatide-coated wells. The amounts of VWF bound were evaluated
by measuring the OD value, as described in Sect. 2. OD values
obtained in the absence of antibody were deﬁned as 100%. The results
represent the means (±SD) of two independent, triplicate experiments
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Arg1395 and Arg1399 [26], and are identical to the GPIb
binding site [7]. It is thus highly likely that NMC4 binding
to the A1 GPIb binding site results in interfering with the
binding to sulfatide.
Lys1348 and four charged residues: Glu1320, His1322,
Asp1323 and His1326 (yellow) between 1320 and 1326,
which represent the B701 epitope, appear to be located
near each other, but on the opposite site of the GPIb- and
sulfatide-binding sites (Fig. 5).
4 Discussion
The current experiment indicated that ten alanine mutants
showed decreased sulfatide-binding, and four novel
Fig. 5 Location of amino acid residues whose mutants showed
decreased binding to sulfatide, and epitopes of botrocetin, mAb
NMC4 and B701 in VWF A1. A spherical surface model of the VWF
A1 domain is shown based on the coordinates reported by Emsley
et al. [36]. Orange indicates residues whose alanine mutants showed
markedly reduced sulfatide binding. Sky blue represents residues
whose mutants showed moderately reduced binding to sulfatide.
Mutation at Lys1362 (red) led to reduced GPIb binding, with normal
binding to botrocetin, suggesting it to be the key residue in VWF-
GPIb binding. Yellow indicates charged amino acid residues within
residues Glu1320-His1326. Mutations at 1320–1326 and Lys1348
(purple) led to signiﬁcant decreases in binding to mAb B701. a
Surface representation of VWF A1 domain from the front. b
Orientations from back. c Top view of the VWF A1 domain. The
orientation of the front and behind is indicated. d The bottom view of
the VWF A1 domain. Orientations from the front and back are
indicated. The coloring of amino acids is the same in all four panels.
In panel c, yellow indicates charged residues within Glu1320-
His1326. Arrows show the binding sites of mAb NMC4, B724, B701,
botrocetin and sulfatide
368 T. Nakayama et al.
123mutations at Arg1392, Arg1395, Arg1399 and Lys1423 led
to a marked reduction (Fig. 2). Our previous studies indi-
cated that these mutants underwent no signiﬁcant
conformational changes [7]. It has been shown that
Lys1362, Arg1392 and Arg1395 are important for binding
to GPIb, among which Lys1362 is located at the center of
the binding surfaces [7]. mAb NMC4 inhibits both risto-
cetin- and botrocetin-induced VWF binding to platelet
GPIb [28], and the crystallographic structure has revealed
that NMC4 interacts directly with the amino acid side
chains of Arg1392, Arg1395 and Arg1399 in the VWF A1
domain [26], thus these sites are its epitope. Also, NMC4
effectively inhibited the sulfatide–VWF interaction
(Fig. 4), suggesting the importance of these residues for
binding not only to GPIb but also to sulfatide. This
observation is supported by recent ﬁndings that sulfatide
inhibits the binding of beads covalently coupled to the
fragment of GPIba to the VWF A1 domain [13].
A previous peptide inhibition study suggested that sul-
fatide binding sites were localized between amino acids,
Lys1332 and Lys1348 [12]. However, our 7 alanine
mutants between K1332A and K1348A showed normal
sulfatide binding (Fig. 2). It is possible that the synthetic
peptide interacted with other surface regions around the
sulfatide binding sites.
It has been also indicated that mAb B724 effectively
inhibited VWF–sulfatide interaction [12]. We previously
showed that a mutation at Lys1423 did not decrease binding
to GPIb, but inhibited binding to B724 [7]. In accordance
with the previous observation that B724 inhibited VWF-
binding to botrocetin [29], it is suggested that Lys1423 is
important not only for binding to botrocetin, but also to
sulfatide. The 3D structure of the VWF-A1 domain reveals
that the three residues, Arg1392, Arg1395 and Arg1399, are
localized as a cluster (Fig. 5), proposing their simultaneous
accessibility to sulfatide.Lys1423, located inthe a5helix, is
isolated from the former three residues, although a further
study may be required to verify the cooperative role of this
amino acid residue.
Our study also identiﬁed the epitope of mAb 701. Two
mutants, (1320–1326) 4A and K1348A, showed signiﬁcant
decrease in binding to B701 (Fig. 3), and residues Glu1320,
His1322 Asp1323, His1326 and Lys1348 are localized in
close proximity (Fig. 5c), suggesting that they include the
B701 epitope. The epitope is, however, located on the
opposite site of the GPIb- and sulfatide- binding site
(Fig. 5c),whichisconsistentwithourobservationthatB701
showednoeffectsonthesulfatide–VWFinteraction(Fig. 4).
The effects of sulfatides on thrombogenesis have been
evaluatedformanyyears,butstillremaincontroversial[30].
The recent ﬁndings of Borthaker et al. showed that sulfatide
inhibits the binding of beads covalently coupled to the
fragment of GPIba to the VWF-A1 domain [13]. The
binding of VWF to GPIb requires conformational change of
VWF, induced by shear stress under irregular blood ﬂow
[24, 31]. Therefore, it is likely that VWF–sulfatide binding
competes with VWF–GPIb binding, and that sulfatides
possess antithrombotic properties under some pathological
conditions,suchassitesofarteriosclerosisorvascularinjury
where the VWF–GPIb interaction initiates thrombus for-
mation [32]. However, interestingly, administration of
sulfatidesintoaratdeep veinthrombosismodelinwhich the
inferior vena cava was ligated led to enhanced thrombus
formation compared to the control, which received an
injection of the vehicle alone [33]. Our result and those of
other studies showed that sulfatides could bind to intact
VWF (with no conformational change) [11, 25]. Thus, sul-
fatides may induce thrombus formation through binding to
intact VWF under conditions whereby blood ﬂow is con-
gestive, in which VWF–GPIb does not play a pivotal role in
thrombus formation [34, 35]. Our in vitro experiments
revealed that mAb NMC4 inhibited the VWF–sulfatide
association in a dose-dependent manner (Fig. 4), suggesting
the possibility that the in vivo neutralization of VWF-
dependent adhesion could lead to a possible intervention
treatment to prevent vaso-occlusion under such condition.
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